8-K: Exelixis Reports Strong Q4 and Fiscal Year 2024 Results, Cabozantinib Franchise Drives Growth

Exelixis announces robust fourth quarter and fiscal year 2024 financial results, driven by the strong performance of its cabozantinib franchise, and provides a corporate update highlighting key milestones and future plans.

Summary

• Exelixis reported total revenues of $567 million for Q4 2024 and $2.17 billion for fiscal year 2024.
• The cabozantinib franchise achieved $1.81 billion in U.S. net product revenues for fiscal year 2024, including $515 million for Q4 2024.
• GAAP diluted EPS was $0.48 for Q4 2024 and $1.76 for fiscal year 2024.
• Non-GAAP diluted EPS was $0.55 for Q4 2024 and $2.00 for fiscal year 2024.
• The company is maintaining its 2025 financial guidance, projecting total revenues between $2.15 billion and $2.25 billion and net product revenues between $1.95 billion and $2.05 billion.
• Exelixis anticipates a potential U.S. regulatory approval for CABOMETYX in advanced neuroendocrine tumors, with a PDUFA target action date of April 3, 2025.
• Zanzalintinib is expected to be a key focus in 2025, with pivotal data milestones anticipated from STELLAR-303, STELLAR-304, and STELLAR-305 trials.
• Merck is expected to initiate two renal cell carcinoma studies evaluating zanzalintinib plus belzutifan this year.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, key milestones achieved, and promising pipeline developments. The company's confidence is reflected in the stock repurchase program and maintained financial guidance.

Positives

• Strong financial performance driven by the cabozantinib franchise.
• Increase in net product revenues due to higher sales volume and average net selling price.
• Collaboration revenues increased due to higher royalty revenues from cabozantinib sales outside the U.S.
• GAAP and non-GAAP net income and EPS increased compared to the previous year.
• Positive ruling in the second cabozantinib ANDA litigation against MSN Pharmaceuticals, Inc.
• Stock repurchase program underway, indicating confidence in the company's financial position.
• Advancement of zanzalintinib and other pipeline candidates through clinical trials.
• Collaboration with Merck to evaluate zanzalintinib in combination with KEYTRUDA and WELIREG.

Negatives

• Research and development expenses for the quarter increased, primarily due to increases in license and other collaboration costs, personnel expenses and higher manufacturing costs.
• Selling, general and administrative expenses for the quarter increased, primarily related to increases in personnel expenses and stock-based compensation expenses.

Risks

• The 2025 financial guidance does not include potential revenues from CABOMETYX in advanced neuroendocrine tumors, making the guidance conservative.
• The company's success depends on the regulatory approval and market acceptance of its products.
• Clinical trial results for zanzalintinib and other pipeline candidates are uncertain.
• Exelixis faces market competition and the potential for generic versions of its marketed products.
• The ongoing litigation regarding cabozantinib patents could impact future revenues.

Future Outlook

Exelixis is maintaining its 2025 financial guidance, projecting total revenues between $2.15 billion and $2.25 billion and net product revenues between $1.95 billion and $2.05 billion. The guidance does not include potential revenues from CABOMETYX in advanced neuroendocrine tumors, pending FDA approval.

Management Comments

• Michael M. Morrissey, Ph.D., President and Chief Executive Officer, stated that Exelixis delivered a strong fourth quarter of 2024, positioning the company well to maximize success in 2025.
• Dr. Morrissey noted the outsized performance of the cabozantinib franchise, generating significant net product revenues.
• Dr. Morrissey expects zanzalintinib to take center stage in 2025 as the next franchise opportunity.

Industry Context

Exelixis is operating in the competitive oncology market, focusing on developing and commercializing innovative treatments for various types of cancer. The company's collaboration with Merck highlights the industry trend of combining different therapies to improve patient outcomes. The positive ruling in the ANDA litigation is crucial for maintaining market exclusivity for cabozantinib.

Comparison to Industry Standards

• Exelixis' cabozantinib franchise competes with other tyrosine kinase inhibitors (TKIs) in the oncology space, such as Pfizer's Sutent (sunitinib) and Novartis' Votrient (pazopanib) in renal cell carcinoma.
• The company's focus on zanzalintinib as a next-generation TKI aligns with the industry's pursuit of more selective and effective therapies.
• The collaboration with Merck is similar to other partnerships in the pharmaceutical industry, where companies combine their expertise and resources to develop novel treatments.
• Exelixis' stock repurchase program is a common practice among publicly traded companies with strong cash flow, indicating confidence in future performance, similar to Amgen and Gilead Sciences.

Legal Proceedings

• The U.S. District Court ruled in Exelixis' favor in the second cabozantinib ANDA litigation against MSN Pharmaceuticals, Inc.
• MSN noticed an appeal to the Court of Appeals for the Federal Circuit, and Exelixis noticed a cross-appeal.
• Exelixis received notice that MSN submitted to the FDA a Paragraph IV certification regarding another Exelixis Orange Book patent: U.S. Patent No. 12,128,039.

Stakeholder Impact

• Shareholders: Positive financial results and stock repurchase program could increase shareholder value.
• Employees: Continued growth and pipeline development may create job opportunities.
• Patients: Advancements in cancer treatments could improve patient outcomes.
• Collaboration Partners: Continued collaboration with partners like Merck could lead to further advancements in cancer therapies.

Next Steps

• Potential commercial launch of CABOMETYX for advanced NET following FDA review.
• Expansion of zanzalintinib's pivotal development program.
• Initial clinical data readouts from STELLAR-001 and STELLAR-002 studies in the first half of 2025.
• Clinical updates from STELLAR-303, -304, and -305 trials in the second half of 2025.
• Accelerating the phase 1 development of XL309.
• Continued progress of phase 1 clinical trials for XB010 and XL495.
• Potentially filing three Investigational New Drug applications for XB628, XB064 and XB371.

Key Dates